Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Accumulated Expenses (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Accumulated Expenses data on record, last reported at $2.8 million in Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 1404.23% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 1404.23% increase, with the full-year FY2025 number at $2.8 million, up 1404.23% from a year prior.
  • Accumulated Expenses reached $2.8 million in Q4 2025 per NBP's latest filing, down from $7.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for NBP hit a ceiling of $92.8 billion in Q4 2021 and a floor of -$7.3 million in Q2 2022.
  • A 5-year average of $7.2 billion and a median of $6.8 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 109616.73% in 2021, then crashed 137.78% in 2025.
  • Tracing NBP's Accumulated Expenses over 5 years: stood at $92.8 billion in 2021, then plummeted by 99.99% to $6.1 million in 2022, then increased by 10.41% to $6.8 million in 2023, then crashed by 103.16% to -$213000.0 in 2024, then skyrocketed by 1404.23% to $2.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for NBP at $2.8 million in Q4 2025, $7.4 million in Q3 2025, and -$1.3 million in Q2 2025.